With late-stage data in Alzheimer’s disease due in the coming months, Athira Pharma’s CEO, Mark Litton,Ph.D., sat down with Hannah Deresiewicz, EVP of Precision AQ, while at the Jefferies Global Healthcare Conference to discuss his excitement for the future and the Company’s novel approach to battling a variety of neurodegenerative diseases.
Precision AQ - Investor Relations & External Communications’ Post
More Relevant Posts
-
New Blood Test Could Predict Parkinson’s Disease 7 Years Before Symptoms. Early Detection of Parkinson’s: AI-Powered Blood Test Identifies Biomarkers Years Before Symptoms, Offering Hope for Proactive Management. https://lnkd.in/g-XTGmn7
To view or add a comment, sign in
-
https://lnkd.in/eneKpi87 Another interesting article linking the gut-brain axis, this time focusing on the association with Parkinson's disease. Reach out to ADM to learn more about the work we are doing in this area and the possible benefits of our Bacillus subtilis PXN21 strain. #gutbrainaxis #psychobiotics #probiotics
Gut problems may be early sign of Parkinson's disease
bbc.co.uk
To view or add a comment, sign in
-
Explore the world of oral health with Norgen’s latest blog, "Saliva Microbiome Analysis as a Diagnostic Tool." 🦷 Discover the roots of oral diseases dating back millennia and unravel the secrets of the human oral microbiome. 🧬 Learn about its impact on dental diseases, systemic conditions like cardiovascular disease and Alzheimer's, and the future of diagnostics. Norgen offers a complete saliva workflow for groundbreaking research. 🦠 Read more: https://lnkd.in/gQ6pDMrZ #Saliva #Microbiome #OralHealth #Diagnostics #Norgenbiotek
To view or add a comment, sign in
-
-
Today, the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health marks October as Liver Awareness Month. Since our founding nearly 2 years ago, we have been working on a three-pronged approach to our research on liver disease and how we are revolutionizing liver care. First, we continue to recruit fellows and faculty working on metabolic health and how it connects to liver injury, inflammation and scarring. Secondly, we are establishing international collaborative partnerships with researchers from different specialties who study diseases that share common biology. By working together, we can share ideas, find new discoveries and develop therapies relevant to a wide array of health issues. Thirdly, we are expanding our expertise in new areas: for example, we now have clinics for illnesses like sarcoidosis, and cholestatic liver disease, in which the bile produced in your liver is slowed or stalled. Above all else, we remain dedicated to patient-centered care. As the Stravitz-Sanyal institute expands, more revolutionary treatment options will become available for patients with liver diseases. #Get2KnowYourLiver #OctoberIs4Livers #liver #VCU
To view or add a comment, sign in
-
-
According to the National Organization for Rare Disorders there are more than 7,000 different rare diseases, of which 95% lack any FDA-approved treatment. From uncovering genetic factors to exploring potential therapies, collaboration among researchers, healthcare professionals, and advocacy groups is vital to advance clinical research and potential treatments. As we approach #RareDiseaseDay, we join the global rare disease community in advocating for increased research and collaboration. Together, we can amplify awareness, accelerate discoveries, and pave the way for innovative treatments, offering hope for the 300 million people worldwide living with a #raredisease. Learn more about Rare Disease Day: https://lnkd.in/gk6hbAF
To view or add a comment, sign in
-
-
Gadoxetate-enhanced MRI is a valuable tool for assessing liver function in clinical trials, a currently unmet need in chronic liver disease. Learn more about our work with gadoxetate here: https://lnkd.in/dNHh8uD8 #liverdisease #clinicaltrials #drugdevelopment
To view or add a comment, sign in
-
Astri Arnesen, the President of the European Federation of Neurological Associations, focuses in this MEDtalk on the importance of disease-specific patient journeys for Huntington's disease. In these patient journeys, the development of the European Reference Network for rare neurological diseases describes the complexity and what the healthcare system and the patients should be aware of. 🔗Follow along as we cover the EAN 2024 congress; https://lnkd.in/dmWquMkt #EAN24
Disease-Specific Patient Journeys for Huntington's Disease
https://bpno.se
To view or add a comment, sign in
-
Astri Arnesen, the President of the European Federation of Neurological Associations, focuses in this MEDtalk on the importance of disease-specific patient journeys for Huntington's disease. In these patient journeys, the development of the European Reference Network for rare neurological diseases describes the complexity and what the healthcare system and the patients should be aware of. 🔗Follow along as we cover the EAN 2024 congress; https://lnkd.in/dz9VJRPC #EAN24
Disease-Specific Patient Journeys for Huntington's Disease
https://bpno.fi
To view or add a comment, sign in